TREVENA INC - TRVN STOCK NEWS

Trevena, Inc. (Nasdaq: TRVN) announced findings from two health economic models presented at the ISPOR 2021 Annual Conference, highlighting significant cost savings for hospitals using OLINVYK (oliceridine) over IV morphine for postoperative care. The models suggest a potential savings of approximately $230,000 per 1,000 patients with OLINVYK, increasing to $364,000 for elderly, obese patients. These findings are aimed at aiding hospital formulary reviews, although actual savings are not guaranteed. OLINVYK is a new opioid analgesic approved by the FDA in August 2020.

Trevena, Inc. (Nasdaq: TRVN) announced results from an exploratory analysis of OLINVYK at the 46th Annual ASRA Meeting. The study found that elderly and obese patients receiving OLINVYK did not have a higher incidence of opioid-induced respiratory depression (OIRD) compared to younger and non-obese patients. The high-risk group showed a low OIRD incidence of 10.8%, compared to 14.6% in low-risk patients. Despite potential risks, OLINVYK may be suitable for complex patients requiring postoperative pain management, but careful monitoring is advised.

Trevena, Inc. (Nasdaq: TRVN) announced that its TRV027, an AT₁ receptor selective agonist, has been selected for an NIH ACTIV trial involving ~300 COVID-19 patients. This trial aims to evaluate TRV027's effectiveness in combating complications from the renin-angiotensin-aldosterone system (RAAS) disruptions in COVID-19 patients. TRV027 intends to mitigate acute lung damage and improve outcomes, including recovery rates and mortality. The study reflects Trevena's commitment to developing innovative therapies for critical health challenges.

Trevena, Inc. (Nasdaq: TRVN) reported its first-quarter 2021 financial results, highlighting a net loss of $9.8 million or $0.06 per share, increasing from the previous year. The company reaffirms its goal of securing 100 formulary approvals for OLINVYK® by year-end and has initiated a clinical study to evaluate OLINVYK's effects on respiratory and cognitive functions. Additionally, TRV027 has been selected for two large COVID-19 trials, and TRV045 is on track for an IND filing aimed at diabetic neuropathic pain. Cash reserves stood at $97.7 million, sufficient for operations through Q4 2022.

Trevena, Inc. (Nasdaq: TRVN) will announce its Q1 2021 financial results on May 6, 2021, before market open. A conference call will be held at 8:00 a.m. ET, featuring key executives including CEO Carrie Bourdow and CFO Barry Shin. Trevena is focused on developing innovative treatments for CNS disorders, with an approved product, OLINVYK™, and a promising pipeline including TRV250 for migraines and TRV734 for opioid use disorder. Investors can access the call via web links provided in the release.

Trevena, Inc. (TRVN), a biopharmaceutical company specializing in CNS disorders, announced that Dr. Mark A. Demitrack will participate in the 4th Annual Sachs Associates Neuroscience Innovation Forum from April 28-30, 2021. He will present on the Pain, Migraine & Addiction Panel on April 29 at 11:50 a.m. ET. The discussion will be available on demand for registered participants. Trevena has one approved product, OLINVYK™, and a pipeline of four investigational drug candidates addressing critical conditions like migraine and opioid use disorder.

Trevena, Inc. has announced that its drug TRV027 has been included in the REMAP-CAP trial, aimed at evaluating treatments for COVID-19. This adaptive Phase 2-Phase 3 trial will involve up to 300 patients and assess TRV027's effectiveness in reducing mortality and organ failure in severely ill patients. Initial data from Imperial College London indicated no safety concerns, supporting the transition to a larger study. TRV027 aims to moderate the renin-angiotensin system, potentially alleviating multi-organ damage and abnormal blood clotting linked to COVID-19.

Trevena, Inc. (Nasdaq: TRVN) announced significant findings at the AMCP 2021 Annual Meeting regarding its product OLINVYK (oliceridine) for postoperative pain management. Health economic models show OLINVYK could save hospitals approximately $230,000 in total care costs per 1,000 patients compared to IV morphine, with potential savings rising to $364,000 for high-risk patients. The studies garnered a Gold Ribbon at the conference, highlighting their value. These results emphasize OLINVYK's potential in enhancing patient care while reducing hospital expenses.

Trevena, Inc. (Nasdaq: TRVN) has appointed Marvin H. Johnson, Jr. to its Board of Directors, with his election set for the 2021 Annual Meeting of Stockholders. Johnson brings over 30 years of experience from Merck & Co., enhancing Trevena's leadership as the company aims to launch its first product, OLINVYK, and advance its CNS pipeline. Concurrently, board members Maxine Gowen and Julie McHugh are retiring, ending their tenures that shaped the company since its inception. This transition is aimed at strengthening the board's expertise amid Trevena's growth phase.